CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤中的过继性细胞治疗
英文原题：Adoptive cellular therapies in multiple myeloma.
查看英文原题
Adoptive cellular therapies in multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
浆细胞骨髓瘤（多发性骨髓瘤）是一种血液癌症，特征为骨髓中浆细胞克隆性增殖。治疗策略逐年演进，FDA每年批准新药。嵌合抗原受体（CAR）疗法是一种先进免疫疗法，通过工程化改造T细胞，使其识别并摧毁癌细胞。近年来，过继细胞疗法已成功用于治疗复发/难治性患者。目前证据不断增加，支持将其更早用于治疗过程，甚至作为自体造血干细胞移植的替代方案。现有研究正在将CAR疗法拓展至实体瘤，并通过创新设计和联合策略提高安全性与疗效。本文旨在简要介绍CAR-T 细胞和NK细胞疗法治疗浆细胞骨髓瘤的历史及最新进展。
展开英文摘要原文
Plasma cell myeloma (multiple myeloma) is a blood cancer characterized by the clonal proliferation of plasma cells in the bone marrow. Treatment strategies evolve year by year, new drugs getting Food and Drug Administration (FDA)-approved each year. Chimeric antigen receptor (CAR) therapies are an advanced form of immunotherapy that engineer T cells to recognize and destroy cancer cells. In recent years, adoptive cellular therapies have been successfully used to treat relapsed or refractory patients.
Now, growing evidence supports their effectiveness when used earlier in treatment, even as an alternative to autologous hematopoietic stem cell transplantation. Ongoing research is expanding CAR therapy to solid tumors and enhancing safety and efficacy through innovative designs and combination strategies. In this paper, we aim to highlight the brief history and the latest advancements in CAR T-cell and NK-cell therapies for plasma cell myeloma.
论文信息
- 作者
- Kegyes D、Borlea B、Damian M、Tigu AB、Nistor M、Cenariu D、Munteanu R、Gulei D
- 第一作者单位
- Department of Personalized Medicine and Rare Diseases, Medfuture Institute for Biomedical Research - Department of Hematology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.Italy
- 通讯作者单位
- Department of Personalized Medicine and Rare Diseases, Medfuture Institute for Biomedical Research - Department of Hematology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Hematology, Ion Chiricuta Cancer Center, Cluj Napoca, Romania. Electronic address: ciprian.tomuleasa@umfcluj.ro.Italy
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Best practice & research. Clinical haematology2025 Sep
- 原文标识
- PubMed 40915705 · DOI 10.1016/j.beha.2025.101638